利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.022 秒)

    COMPOSITIONS AND METHODS FOR ALTERING WNT AUTOCRINE SIGNALING
    1.
    发明申请
    COMPOSITIONS AND METHODS FOR ALTERING WNT AUTOCRINE SIGNALING 审中-公开
    用于改变WNT自动信号信号的组合物和方法

    公开(公告)号：WO2006055635A3

    公开(公告)日：2007-03-29

    申请号：PCT/US2005041531

    申请日：2005-11-15

    申请人： SINAI SCHOOL MEDICINE ,  BAFICO ANNA ,  AARONSON STUART

    发明人： BAFICO ANNA ,  AARONSON STUART

    IPC分类号： A61K38/00 ,  A61K48/00

    CPC分类号： A61K38/1703 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a compound that alters Wnt signaling. The compound that alters Wnt signaling can be a Wnt antagonist, a Wnt receptor antagonist, or a combination thereof.

    摘要翻译： 本发明涉及用于治疗其中自分泌Wnt标准信号通路被激活的癌症的化合物和方法。 具体地，提供了通过使这样的肿瘤细胞与改变Wnt信号传导的化合物接触来抑制肿瘤细胞生长或致敏癌细胞进行治疗的方法。 改变Wnt信号传导的化合物可以是Wnt拮抗剂，Wnt受体拮抗剂或其组合。

    METHODS OF DETERMINING WHETHER THE WNT SIGNALING PATHWAY IS UPREGULATED IN A TUMOR
    4.
    发明申请
    METHODS OF DETERMINING WHETHER THE WNT SIGNALING PATHWAY IS UPREGULATED IN A TUMOR 审中-公开
    确定WNT信号通路在肿瘤中升高的方法

    公开(公告)号：WO2010121269A1

    公开(公告)日：2010-10-21

    申请号：PCT/US2010/031647

    申请日：2010-04-19

    申请人： MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY ,  AARONSON, Stuart ,  AKIRI, Gal ,  VIJAYAKUMAR, Sapna

    发明人： AARONSON, Stuart ,  AKIRI, Gal ,  VIJAYAKUMAR, Sapna

    IPC分类号： G01N33/48 ,  G01N33/53

    CPC分类号： G01N33/57484 ,  A61K33/24 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/5748 ,  G01N2333/47

    摘要： The invention demonstrates that canonical Wnt signaling is activated in certain primary tumors and tumor cell lines in the absence of ?-catenin or APC mutations and that inhibition of such activated canonical Wnt signaling in such tumor cells inhibits tumor growth and, at least in some cases, induces death of tumor cells. As further demonstrated herein, the activation of canonical Wnt signaling is associated with a higher rate of cancer recurrence in patients with Stage I Non-Small Cell Lung Cancer (NSCLC), which provides a new method for cancer prognosis, wherein activation of canonical Wnt signaling reflects a more aggressive tumor phenotype suggesting the need for a more aggressive therapy.

    摘要翻译： 本发明表明，在不存在β-联蛋白或APC突变的情况下，在某些原发性肿瘤和肿瘤细胞系中激活了典型的Wnt信号传导，并且这种肿瘤细胞中这种激活的典型Wnt信号传导的抑制抑制肿瘤生长，并且至少在某些情况下 ，诱导肿瘤细胞死亡。 如本文进一步证实的，典型的Wnt信号传导的激活与I期非小细胞肺癌（NSCLC）患者的更高的癌症复发率相关，其提供了癌症预后的新方法，其中规范的Wnt信号传导 反映了更积极的肿瘤表型，表明需要进行更积极的治疗。

    COMPOSITIONS AND METHODS FOR ALTERING WNT AUTOCRINE SIGNALING
    7.
    发明申请
    COMPOSITIONS AND METHODS FOR ALTERING WNT AUTOCRINE SIGNALING 审中-公开
    改变WNT自动信号信号的组合物和方法

    公开(公告)号：WO2006055635A9

    公开(公告)日：2006-08-24

    申请号：PCT/US2005041531

    申请日：2005-11-15

    申请人： ITY MOUNT SINAI SCHOOL OF MEDI ,  BAFICO ANNA ,  AARONSON STUART

    发明人： BAFICO ANNA ,  AARONSON STUART

    IPC分类号： A01N43/04

    CPC分类号： A61K38/1703 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a compound that alters Wnt signaling. The compound that alters Wnt signaling can be a Wnt antagonist, a Wnt receptor antagonist, or a combination thereof.

    摘要翻译： 本发明涉及用于治疗其中自分泌Wnt典型信号传导途径被激活的癌症的化合物和方法。 具体而言，提供了通过使肿瘤细胞与改变Wnt信号传导的化合物接触来抑制肿瘤细胞生长或使癌细胞对治疗敏感的方法。 改变Wnt信号传导的化合物可以是Wnt拮抗剂，Wnt受体拮抗剂或其组合。

    COMPOSITIONS AND METHODS FOR ALTERING WNT AUTOCRINE SIGNALING
    8.
    发明申请
    COMPOSITIONS AND METHODS FOR ALTERING WNT AUTOCRINE SIGNALING 审中-公开
    用于改变WNT自动信号信号的组合物和方法

    公开(公告)号：WO2006055635A2

    公开(公告)日：2006-05-26

    申请号：PCT/US2005/041531

    申请日：2005-11-15

    申请人： MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY ,  BAFICO, Anna ,  AARONSON, Stuart

    发明人： BAFICO, Anna ,  AARONSON, Stuart

    IPC分类号： A01N43/04

    CPC分类号： A61K38/1703 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a compound that alters Wnt signaling. The compound that alters Wnt signaling can be a Wnt antagonist, a Wnt receptor antagonist, or a combination thereof.

    摘要翻译： 本发明涉及治疗癌症的化合物和方法，其中自分泌Wnt标准信号通路被激活。 具体地，提供了一种抑制肿瘤细胞生长或使癌细胞敏化以通过使这种肿瘤细胞与改变Wnt信号传导的化合物接触来治疗的方法。 改变Wnt信号传导的化合物可以是Wnt拮抗剂，Wnt受体拮抗剂或其组合。

    cDNA CLONING OF POTENTIALLY TRANSFORMING HUMAN ras-RELATED ONCOGENES
    9.
    发明申请
    cDNA CLONING OF POTENTIALLY TRANSFORMING HUMAN ras-RELATED ONCOGENES 审中-公开
    可能转化人类ras相关肿瘤的cDNA克隆

    公开(公告)号：WO1995032223A1

    公开(公告)日：1995-11-30

    申请号：PCT/US1995006420

    申请日：1995-05-24

    申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  AARONSON, Stuart, A.

    发明人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  CHAN, Andrew ,  MIKI, Toru

    IPC分类号： C07K14/82

    CPC分类号： C07K14/82 ,  C12Q1/6886 ,  C12Q2600/156

    摘要： The oncogene of the present invention, isolated by expression cloning from a human ovarian cancer is a mutant of TC21. The present invention teaches that ras-related genes not thought to have transforming potential can contribute importantly to cancers which have been refractory to oncogene detection. The present invention teaches that another ras relative gene, R-ras, which was previously reported to lack transforming potential, has transforming capacity as well. Thus, these and other genes similarly related to prototype and activated by analogous mechanisms may be important in the diagnosis and prognosis of certain cancers, as well as be critical in the design of rational approaches to therapy of cancers in which they play a role.

    摘要翻译： 通过从人卵巢癌的表达克隆分离的本发明的致癌基因是TC21的突变体。 本发明教导了未被认为具有转化潜力的ras相关基因可以重要地对致癌基因检测难治的癌症起重要作用。 本发明教导了另一种ras相对基因R-ras，其先前报道为缺乏转化潜力，也具有转化能力。 因此，与原型相似的这些和其他基因和通过类似机制激活的基因在某些癌症的诊断和预后中可能是重要的，并且对于其中起作用的癌症的治疗的理性方法的设计至关重要。